DexCom Investors Alerted of Class Action Lawsuit Deadline in October 2024

In New York, on September 30, 2024, Levi & Korsinsky, LLP announced a class action lawsuit against Lululemon Athletica Inc. The lawsuit targets investors who suffered losses due to alleged securities fraud occurring between December 7, 2023, and July 24, 2024. The complaint claims that the company misled investors about its business performance, particularly regarding inventory issues and a failed product launch, which led to stagnating sales in the Americas region. Investors have until October 7, 2024, to apply as lead plaintiffs in the case. Additionally, The Gross Law Firm issued notices for two other companies, Outset Medical, Inc. and DexCom, Inc., regarding similar class action lawsuits. Outset Medical's lawsuit involves allegations of misleading statements about its Tablo products, which were marketed for unapproved uses, impacting sales and revenue growth. The class period for this case spans from August 1, 2022, to August 7, 2024, with a lead plaintiff deadline of October 28, 2024. DexCom's lawsuit arises from a significant drop in stock price following the announcement of disappointing financial results and lowered revenue guidance on July 25, 2024. The class period for DexCom extends from January 8, 2024, to July 25, 2024, with a lead plaintiff deadline of October 21, 2024. These lawsuits reflect ongoing concerns about corporate transparency and accountability in the financial markets. Investors in these companies are encouraged to register for the class actions to potentially recover losses, as participation does not require serving as a lead plaintiff. The legal firms involved have established reputations for advocating for shareholders' rights and pursuing justice in securities fraud cases.